AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8006492 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary nursing and discharge teaching (n = 36)
Number of subjects: 72
Study 8006492 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 36)
Number of subjects: 72
Study 8006492 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (primary and control)
Number of subjects: 72
Study 2912719 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand-name carbamazepine (Tegretol)
Number of subjects: 10
Study 2912719 — intervention group
Group type: COMPARATOR
Intervention: Generic carbamazepine (Parke-Davis)
Number of subjects: 10
Study 814396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine
Number of subjects: 40
Study 31067189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure target <130 mm Hg
Number of subjects: 4983
Study 31067189 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure target <140 mm Hg
Number of subjects: 4983
Study 31067189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure target <130 mm Hg (after excluding patients with higher GFR and intensive glycemic control)
Number of subjects: 4983
Study 31067189 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure target <140 mm Hg (after excluding patients with higher GFR and intensive glycemic control)
Number of subjects: 4983
Study 28145064 — intervention group
Group type: EXPERIMENTAL
Intervention: Pair-based refund (P-PBR)
Number of subjects: 77
Study 28145064 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual weight loss with individual refund (I-IR)
Number of subjects: 77
Study 28145064 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner with individual refund (P-IR)
Number of subjects: 77
Study 28145064 — intervention group
Group type: COMPARATOR
Intervention: No MCC (comparison)
Number of subjects: 77
Study 24878686 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted smoking cessation intervention (8 weekly 40-min counseling sessions with Korean-specific cultural elements)
Number of subjects: 109
Study 24878686 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation intervention (8 weekly 10-min counseling sessions not culturally adapted)
Number of subjects: 109
Study 23134470 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily everolimus (7.5 mg)
Number of subjects: 39
Study 23134470 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly everolimus (70 mg)
Number of subjects: 39
Study 23134470 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily everolimus (7.5 mg) in HBsAg‐seropositive patients
Number of subjects: 39
Study 23134470 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly everolimus (70 mg) in HBsAg‐seropositive patients
Number of subjects: 39
Study 21606230 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered bone marrow aspiration and biopsy device
Number of subjects: 50
Study 21606230 — intervention group
Group type: COMPARATOR
Intervention: Manual technique
Number of subjects: 50
Study 18206247 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (eicosapentaenoic and docosahexaenoic acids), 1.9g/day for 8 weeks
Number of subjects: 59
Study 18206247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 16802891 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Intelligence (EI)
Number of subjects: 200
Study 16802891 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroticism
Number of subjects: 200
Study 16802891 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscientiousness
Number of subjects: 200
Study 16802891 — intervention group
Group type: COMPARATOR
Intervention: Task-induced stress conditions
Number of subjects: 200
Study 15199081 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER 20 mg q12h for 1 day
Number of subjects: 126
Study 15199081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 15199081 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER
Number of subjects: 126
Study 12815774 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (7.5% - 1 ml/kg b.w.)
Number of subjects: 16
Study 9297272 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hemofiltration (CHF)
Number of subjects: 21
Study 9297272 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amputation and restoration of diuresis combined with CHF
Number of subjects: 21
Study 7686013 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral treatment
Number of subjects: 34
Study 7686013 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 34
Study 2952435 — intervention group
Group type: EXPERIMENTAL
Intervention: Random blood glucose measurement (thresholds: 6.1 mmol/l within 2 h of eating, 5.6 mmol/l at greater than 2 h of food)
Number of subjects: 110
Study 2952435 — intervention group
Group type: COMPARATOR
Intervention: Formal oral glucose tolerance test
Number of subjects: 110
Study 29630800 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% w/w stannous fluoride dentifrice
Number of subjects: 104
Study 29630800 — intervention group
Group type: COMPARATOR
Intervention: Sodium monofluorophosphate (SMFP) dentifrice
Number of subjects: 104
Study 28767209 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant (15 mg/d)
Number of subjects: 72
Study 28767209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 26184339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral methods of exercise support
Number of subjects: 108
Study 26184339 — intervention group
Group type: COMPARATOR
Intervention: Manual-based self-help for nutrition and exercise plus brief phone follow-ups
Number of subjects: 108
Study 23515985 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid total hip arthroplasty group
Number of subjects: 40
Study 23515985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt-chromium (CoCr) total hip arthroplasty group
Number of subjects: 40
Study 23515985 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium total hip arthroplasty group
Number of subjects: 40
Study 23515985 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 21725509 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonography (EUS) for locoregional staging
Number of subjects: 62
Study 19105461 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved splint
Number of subjects: 92
Study 19105461 — intervention group
Group type: COMPARATOR
Intervention: Traditional splint
Number of subjects: 92
Study 17000363 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver
Number of subjects: 42
Study 17000363 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic assessment of left atrial function
Number of subjects: 42
Study 15526194 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry odor
Number of subjects: 0
Study 15526194 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy sauce odor
Number of subjects: 0
Study 15526194 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined strawberry odor
Number of subjects: 0
Study 15526194 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined soy sauce odor
Number of subjects: 0
Study 15526194 — intervention group
Group type: COMPARATOR
Intervention: Odorless water
Number of subjects: 0
Study 11748094 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricle (LV) stimulation at the lateral free wall
Number of subjects: 30
Study 11748094 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BV) stimulation at the lateral free wall
Number of subjects: 30
Study 11748094 — intervention group
Group type: COMPARATOR
Intervention: Left ventricle (LV) stimulation at the anterior wall
Number of subjects: 30
Study 11748094 — intervention group
Group type: COMPARATOR
Intervention: Biventricular (BV) stimulation at the anterior wall
Number of subjects: 30
Study 9268234 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 5 mg/day
Number of subjects: 36
Study 9268234 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 10 mg/day
Number of subjects: 36
Study 8337639 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia with intravenous sedation
Number of subjects: 125
Study 8337639 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 125
Study 3526572 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management (expectant management)
Number of subjects: 317
Study 3526572 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin induction
Number of subjects: 317
Study 29954367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Modification (ILSM) program
Number of subjects: 256
Study 29954367 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 256
Study 29954367 — intervention group
Group type: EXPERIMENTAL
Intervention: ILSM program
Number of subjects: 256
Study 26490353 — intervention group
Group type: COMPARATOR
Intervention: Fostamatinib 50-200 mg (single and multiple dosing)
Number of subjects: 80
Study 26490353 — intervention group
Group type: COMPARATOR
Intervention: Fostamatinib 150 mg (single dose)
Number of subjects: 80
Study 26490353 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 and 200 mg (open-label study)
Number of subjects: 80
Study 26490353 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib (all doses)
Number of subjects: 80
Study 26490353 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib 200 mg
Number of subjects: 80
Study 26490353 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried blood spot (DBS) sampling
Number of subjects: 80
Study 24384459 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief educational intervention (5-10 min group HPV educational intervention)
Number of subjects: 131
Study 24384459 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief educational intervention
Number of subjects: 131
Study 24384459 — intervention group
Group type: COMPARATOR
Intervention: Control group (survey completion prior to education)
Number of subjects: 131
Study 22795435 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Number of subjects: 0
Study 22795435 — intervention group
Group type: COMPARATOR
Intervention: Sublobar resection (with or without brachytherapy)
Number of subjects: 0
Study 18832427 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10-20 mg/day (fixed 10 mg/day in Study 2) with venlafaxine 75 mg/day
Number of subjects: 498
Study 18832427 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10-20 mg/day with escitalopram 10 mg/day
Number of subjects: 498
Study 18832427 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole 2-20 mg/day (adjunctive therapy)
Number of subjects: 498
Study 18695468 — intervention group
Group type: COMPARATOR
Intervention: Vacuum-assisted closure (VAC)
Number of subjects: 51
Study 18695468 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglactin mesh (MESH)
Number of subjects: 51
Study 11446908 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-sulbactam 875/125 mg
Number of subjects: 12
Study 11446908 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate 875/125 mg
Number of subjects: 12
Study 11446908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam 125 mg
Number of subjects: 12
Study 9506730 — intervention group
Group type: EXPERIMENTAL
Intervention: G+T (three large gin with regular tonics, 0.5 g/kg alcohol and 60 g carbohydrate)
Number of subjects: 8
Study 9506730 — intervention group
Group type: EXPERIMENTAL
Intervention: G alone (same amount of alcohol with Slim‐line tonic, 0.5 g carbohydrate)
Number of subjects: 8
Study 9506730 — intervention group
Group type: COMPARATOR
Intervention: T alone (regular tonic without alcohol)
Number of subjects: 8
Study 9506730 — intervention group
Group type: EXPERIMENTAL
Intervention: G+T
Number of subjects: 8
Study 7890893 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐2a interferon, 1 megaunit thrice weekly for 6 months
Number of subjects: 53
Study 7890893 — intervention group
Group type: COMPARATOR
Intervention: Control group (no maintenance treatment)
Number of subjects: 53
Study 7890893 — intervention group
Group type: COMPARATOR
Intervention: Both groups (treated and control)
Number of subjects: 53
Study 3126012 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (NTG) 10 mg/24 h
Number of subjects: 10
Study 3126012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31292822 — intervention group
Group type: EXPERIMENTAL
Intervention: Type D personality
Number of subjects: 1116
Study 31292822 — intervention group
Group type: COMPARATOR
Intervention: No Type D personality
Number of subjects: 1116
Study 27337519 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribulus terrestris (750 mg in three divided doses for three months)
Number of subjects: 30
Study 25977745 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.5 mg three times a day
Number of subjects: 40
Study 25977745 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (mPSL) 1 mg/kg three times a day
Number of subjects: 40
Study 23681085 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg/day)
Number of subjects: 404
Study 23681085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 21972156 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg of nitroglycerin plus 2.5 mg of verapamil (Group 1)
Number of subjects: 30
Study 21972156 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of verapamil alone (Group 2)
Number of subjects: 30
Study 21972156 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group 1 and Group 2
Number of subjects: 30
Study 18775652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol and dexamethasone treatment under basal conditions in responders
Number of subjects: 0
Study 18775652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol and dexamethasone treatment after stimulation with phytohemagglutinin in responders
Number of subjects: 0
Study 18775652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol treatment in responders
Number of subjects: 0
Study 18775652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol and dexamethasone treatment in responders
Number of subjects: 0
Study 17067450 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 711
Study 17067450 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical management
Number of subjects: 711
Study 12712826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone 2 x 1.0 g i.v. daily (group I = 20 persons)
Number of subjects: 40
Study 12712826 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin 1 x 0.5 g (group II = 20 persons)
Number of subjects: 40
Study 12712826 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 40
Study 12712826 — intervention group
Group type: COMPARATOR
Intervention: Cefoperazone
Number of subjects: 40
Study 10613936 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion imaging-guided strategy (SPECT imaging results unblinded to the physician)
Number of subjects: 46
Study 10613936 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy (results of the imaging test blinded to the physician)
Number of subjects: 46
Study 9103292 — intervention group
Group type: EXPERIMENTAL
Intervention: 25,000 IU retinol daily for 5 years
Number of subjects: 0
Study 9103292 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-10 mg isotretinoin daily for 3 years
Number of subjects: 0
Study 9103292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8397560 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-enriched diet (40 to 80 gm of fiber per day)
Number of subjects: 0
Study 8397560 — intervention group
Group type: COMPARATOR
Intervention: Moderate-fiber dose (40 to 60 gm)
Number of subjects: 0
Study 8397560 — intervention group
Group type: COMPARATOR
Intervention: High-fiber dose (70 to 80 gm)
Number of subjects: 0
Study 8397560 — intervention group
Group type: COMPARATOR
Intervention: American Diabetes Association recommended diet (20 gm or less of fiber)
Number of subjects: 0
Study 30382392 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor training (SMT), N = 10
Number of subjects: 40
Study 30382392 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBV), N = 10
Number of subjects: 40
Study 30382392 — intervention group
Group type: COMPARATOR
Intervention: Oncological control group, N = 10
Number of subjects: 40
Study 30382392 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group, N = 10
Number of subjects: 40
Study 29582637 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing exercises (University of Texas, MD Anderson Cancer Center Swallowing Exercise Protocol)
Number of subjects: 60
Study 29582637 — intervention group
Group type: COMPARATOR
Intervention: Control group (no swallowing exercises)
Number of subjects: 60
Study 29582637 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing thin liquids
Number of subjects: 60
Study 29582637 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing thick liquids
Number of subjects: 60
Study 29582637 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing soft food
Number of subjects: 60
Study 29582637 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing hard food
Number of subjects: 60
Study 29582637 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing dry food
Number of subjects: 60
Study 29582637 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing saliva
Number of subjects: 60
Study 28039399 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity exercise (VIG; n = 18)
Number of subjects: 38
Study 28039399 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity exercise (MOD; n = 20)
Number of subjects: 38
Study 24491067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) including a minimum of 90 minutes of adapted physical activity 5 days/week
Number of subjects: 100
Study 24491067 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 22182258 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic chewing gum containing L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289
Number of subjects: 25
Study 22182258 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 25
Study 22182258 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic chewing gum
Number of subjects: 25
Study 20410514 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up approach (percutaneous drainage followed by minimally invasive retroperitoneal necrosectomy if necessary)
Number of subjects: 88
Study 20410514 — intervention group
Group type: COMPARATOR
Intervention: Open necrosectomy
Number of subjects: 88
Study 20410514 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up approach
Number of subjects: 88
Study 18622999 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led patient education interventions
Number of subjects: 7
Study 16643581 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg haloperidol in 500 mL of normal saline
Number of subjects: 40
Study 16643581 — intervention group
Group type: COMPARATOR
Intervention: 500 mL of normal saline (placebo)
Number of subjects: 40
Study 16643581 — intervention group
Group type: EXPERIMENTAL
Intervention: Open trial with haloperidol after placebo failure
Number of subjects: 40
Study 16643581 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects of haloperidol
Number of subjects: 40
Study 16643581 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse after treatment
Number of subjects: 40
Study 12826040 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ZD9331 (n=30), on days 1 and 8 of a 3‐week cycle
Number of subjects: 55
Study 12826040 — intervention group
Group type: COMPARATOR
Intervention: Intravenous gemcitabine (n=25), once a week for 7 weeks followed by a 1‐week rest, then on days 1, 8 and 15 of a 4‐week cycle
Number of subjects: 55
Study 11392162 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated essential hypertension
Number of subjects: 25
Study 11392162 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control)
Number of subjects: 25
Study 8794969 — intervention group
Group type: EXPERIMENTAL
Intervention: Chairside test measuring GCF levels of AST
Number of subjects: 121
Study 8794969 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (for patients)
Number of subjects: 121
Study 8794969 — intervention group
Group type: COMPARATOR
Intervention: Supragingival prophylaxis (for control subjects)
Number of subjects: 121
Study 8794969 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements of GCF volume, gingival inflammation, and probing depth
Number of subjects: 121
Study 1377838 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental enteral diet with arginine, RNA, and omega-3 fatty acids
Number of subjects: 85
Study 1377838 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral diet
Number of subjects: 85
Study 6696222 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural methadone
Number of subjects: 178
Study 6696222 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 178
Study 6696222 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 178
Study 31331907 — intervention group
Group type: EXPERIMENTAL
Intervention: Exubera (insulin human [rDNA origin], inhaled powder)
Number of subjects: 7439
Study 31331907 — intervention group
Group type: COMPARATOR
Intervention: Other diabetes treatments (control)
Number of subjects: 7439
Study 29992747 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM) intervention (n = 60)
Number of subjects: 115
Study 29992747 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition (n = 51)
Number of subjects: 115
Study 26875171 — intervention group
Group type: EXPERIMENTAL
Intervention: With peers
Number of subjects: 207
Study 26875171 — intervention group
Group type: COMPARATOR
Intervention: Alone
Number of subjects: 207
Study 24818542 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravenous ondansetron
Number of subjects: 258
Study 24818542 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg intravenous metoclopramide
Number of subjects: 258